|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
115,049,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Annexon is a clinical-stage biopharmaceutical company developing a class of complement medicines designed to stop the classical complement pathway at its start, C1q, in order to bring therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Co. is developing a pipeline of product candidates designed to block the activity of C1q and the entire classical complement pathway for a range of complement-mediated diseases. Co.'s pipeline includes three clinical-stage assets across three therapeutic franchises: autoimmune, neurodegenration and ophtamology. Co. its developing its primary candidate, ANX005.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
3,200 |
19,200 |
675,600 |
Total Buy Value |
$0 |
$17,056 |
$105,123 |
$1,787,236 |
Total People Bought |
0 |
1 |
1 |
3 |
Total Buy Transactions |
0 |
1 |
6 |
10 |
Total Shares Sold |
0 |
42,926 |
72,328 |
135,318 |
Total Sell Value |
$0 |
$126,438 |
$314,121 |
$614,834 |
Total People Sold |
0 |
6 |
6 |
6 |
Total Sell Transactions |
0 |
9 |
17 |
29 |
End Date |
2025-02-23 |
2024-11-22 |
2024-05-24 |
2023-05-25 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
|
2025-02-18 |
4 |
S |
$2.91 |
$24,284 |
D/D |
(8,345) |
61,237 |
|
- |
|
Dananberg Jamie |
CHIEF MEDICAL OFFICER |
|
2025-02-18 |
4 |
S |
$2.96 |
$16,342 |
D/D |
(5,521) |
33,479 |
|
- |
|
Lew Jennifer |
EVP & CHIEF FINANCIAL OFFICER |
|
2025-02-18 |
4 |
S |
$2.92 |
$20,183 |
D/D |
(6,912) |
77,770 |
|
- |
|
Overdorf Michael |
EVP & CHIEF BUSINESS OFFICER |
|
2025-02-18 |
4 |
S |
$2.95 |
$19,523 |
D/D |
(6,618) |
86,579 |
|
- |
|
Artis Dean Richard |
EVP & CHIEF SCIENTIFIC OFFICER |
|
2025-02-18 |
4 |
S |
$2.97 |
$16,380 |
D/D |
(5,515) |
83,814 |
|
- |
|
Overdorf Michael |
EVP & CHIEF BUSINESS OFFICER |
|
2025-02-13 |
4 |
S |
$2.99 |
$4,261 |
D/D |
(1,425) |
93,197 |
|
- |
|
Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
|
2025-02-13 |
4 |
S |
$2.99 |
$5,331 |
D/D |
(1,783) |
69,582 |
|
- |
|
Lew Jennifer |
EVP & CHIEF FINANCIAL OFFICER |
|
2025-02-13 |
4 |
S |
$2.98 |
$5,322 |
D/D |
(1,786) |
84,682 |
|
- |
|
Love Douglas |
PRESIDENT AND CEO |
|
2025-02-13 |
4 |
S |
$2.95 |
$14,812 |
D/D |
(5,021) |
351,554 |
|
- |
|
Love Douglas |
PRESIDENT AND CEO |
|
2025-01-06 |
4 |
OE |
$1.41 |
$53,556 |
D/D |
37,994 |
356,575 |
|
- |
|
Carson William H. |
|
|
2024-12-02 |
4 |
AB |
$5.33 |
$17,056 |
D/D |
3,200 |
25,600 |
|
- |
|
Love Douglas |
PRESIDENT AND CEO |
|
2024-10-30 |
4 |
OE |
$1.85 |
$211,742 |
D/D |
114,449 |
310,570 |
|
- |
|
Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
|
2024-10-15 |
4 |
AS |
$7.41 |
$40,073 |
D/D |
(5,408) |
71,365 |
|
- |
|
Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
|
2024-10-15 |
4 |
OE |
$1.85 |
$10,005 |
D/D |
5,408 |
76,773 |
|
- |
|
Carson William H. |
|
|
2024-10-01 |
4 |
AB |
$5.97 |
$19,104 |
D/D |
3,200 |
22,400 |
|
- |
|
Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
|
2024-09-19 |
4 |
AS |
$7.10 |
$31,950 |
I/I |
(4,500) |
0 |
|
- |
|
Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
|
2024-09-12 |
4 |
AS |
$6.16 |
$33,880 |
I/I |
(5,500) |
4,500 |
|
- |
|
Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
|
2024-09-05 |
4 |
AS |
$5.64 |
$31,020 |
I/I |
(5,500) |
10,000 |
|
- |
|
Carson William H. |
|
|
2024-09-03 |
4 |
AB |
$5.48 |
$17,536 |
D/D |
3,200 |
19,200 |
|
- |
|
Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
|
2024-08-29 |
4 |
AS |
$5.95 |
$32,725 |
I/I |
(5,500) |
15,500 |
|
- |
|
Carson William H. |
|
|
2024-08-01 |
4 |
AB |
$6.24 |
$19,968 |
D/D |
3,200 |
16,000 |
|
- |
|
Lew Jennifer |
EVP & CHIEF FINANCIAL OFFICER |
|
2024-07-15 |
4 |
S |
$6.03 |
$6,657 |
D/D |
(1,104) |
86,468 |
|
- |
|
Overdorf Michael |
EVP & CHIEF BUSINESS OFFICER |
|
2024-07-15 |
4 |
S |
$6.02 |
$4,720 |
D/D |
(784) |
94,622 |
|
- |
|
Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
|
2024-07-15 |
4 |
S |
$6.02 |
$6,658 |
D/D |
(1,106) |
71,365 |
|
- |
|
Carson William H. |
|
|
2024-07-01 |
4 |
AB |
$5.00 |
$16,000 |
D/D |
3,200 |
12,800 |
|
- |
|
115 Records found
|
|
Page 1 of 5 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|